Results 191 to 200 of about 387,352 (250)

Yeast Gcn2 retains activity following humanization of its auto‐phosphorylation region

FEBS Open Bio, EarlyView.
Using Saccharomyces cerevisiae as a model to study Gcn2 activation and regulation is limited by the lack of antibodies detecting phosphorylated Gcn2. To overcome this, we engineered Gcn2‐HsC, a yeast Gcn2 variant recognizable by commercial anti‐human phospho‐GCN2 antibodies.
Reuben A. Anderson, Anja H. Schiemann, Evelyn Sattlegger   +2 more
wiley   +1 more source

Cost-Effectiveness Analysis of Bimekizumab against Interleukin-23 Inhibitors in Patients with Plaque Psoriasis in Japan. [PDF]

Dermatol Ther (Heidelb)
Igarashi A, Shiraishi K, Saito S, Kudo T, Iizuka Y, Yamamura E, Hase M.   +6 more
europepmc   +1 more source

MagmaFlow: A desktop platform for artificial intelligence‐driven expression analysis

FEBS Open Bio, EarlyView.
MagmaFlow is a free, no‐code platform for gene expression analysis. It generates interactive volcano plots, links genes to literature, pathways, and diseases, prioritizes candidates using millions of publications, identifies affected biological processes, builds network diagrams, and exports publication‐ready figures and reports for macOS and Windows ...
Carlos E. Buss, Ao Li, Eduardo H. Gilglioni, Mayank Bansal, Sumeet Pal Singh, Latifa Bakiri, Alessandra K. Cardozo, Esteban N. Gurzov   +7 more
wiley   +1 more source

Immunosenescence in Older Patients with Psoriasis: Mechanistic Insights and Opportunities for Biologic Therapy. [PDF]

Psoriasis (Auckl)
Wang W, Zha S, Sun L, Zhou D.
europepmc   +1 more source

Hidradenitis suppurativa and psoriasis: shared immunological links with metabolic-associated steatotic liver disease. [PDF]

Front Immunol
Chng WQ, Liew JJ, Liew CF, Muthiah M, Zheng MH, Oon HH.   +5 more
europepmc   +1 more source

Current and Emerging Therapies Targeting the IL-23/IL-17 Axis in Psoriasis. [PDF]

Biomol Ther (Seoul)
Han SJ, Jung GY, Lee GC, Ki DH, Kim BS.
europepmc   +1 more source

Impact of biologic class and treatment line on psoriatic arthritis risk in psoriasis: a population-based cohort study. [PDF]

RMD Open
Watad A, Elizur Y, Hen O, David P, Patt YS, Gendelman O, Nachman A, Zabotti A, Lidar M, McGonagle D, Amital H.   +10 more
europepmc   +1 more source

Vitamin D Receptor-Macrophage-IL-23 Axis in Inflammatory Bowel Disease: Pathogenic Mechanisms and Therapeutic Hope. [PDF]

J Clin Med
Grigoraș A, Ghemiș L, Goriuc A, Murariu A, Fiterman N, Jdid N, Blaga T, Foia GL.   +7 more
europepmc   +1 more source

Research Progress of IL-23 Inhibitors in the Treatment of Crohn’s Disease

Advances in Clinical Medicine
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Biologics update: IL‐23 inhibitors

Dermatological Reviews, 2021
AbstractIntroductionIL‐23 inhibitors have shown long‐term efficacy and safety for the treatment of moderate‐to‐severe plaque psoriasis in adults. Guselkumab has also been approved to treat psoriatic arthritis while tildrakizumab and risankizumab are currently under investigation for treating psoriatic arthritis.
Julie Hong, Edward Hadeler, Megan Mosca, Mimi Chung, Samuel Yeroushalmi, Marwa Hakimi, Wilson Liao, Tina Bhutani   +7 more
openaire   +1 more source